Patients with at least four abdominal pain attacks per month, each lasting at least two hours, experienced significant pain relief as early as 20 min post-administration

Areas of interest include, but are not limited to: Classic antidiabetic, anti-obesity and cardioprotective effects Cardiovascular outcomes and mechanistic correlates Endothelial and vascular biology Myocardial metabolism and heart failure subtypes Novel renal and hepatoprotective actions Optimization and individualized use of existing GLP-1 receptor agonists Development of novel GLP-1 receptor agonists and multi-agonist (dual and triple) strategies Emerging extra-metabolic actions, including anti-inflammatory and neuroprotective effects Combination therapies, including co-formulations with insulin or SGLT2 inhibitors Innovative delivery systems, including non-injectable and implantable approaches Real-world comparative effectiveness, long-term safety, adherence and treatment durability This Collection welcomes original research, translational studies, and comprehensive reviews and meta-analyses that provide novel mechanistic insight or clinically relevant evidence to advance understanding of the expanding role of incretin-based therapies in cardiometabolic medicine

Consider a multivitamin or key nutrient supplements if intake is low
(2016a) 21:80218
GLP-1 receptor agonists do not directly affect thyroid hormone production or metabolism
Closed both skin and duodenal defect in BPC 157 rats (fistula closed, b ) (Skorjanec et al., 2015)